{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte-colony+stimulating+factor&page=14",
    "query": {
      "intervention": "Granulocyte-colony stimulating factor",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 1385,
    "total_pages": 139,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte-colony+stimulating+factor&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte-colony+stimulating+factor&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:16:06.977Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03707262",
      "title": "Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Transplant Rejection",
        "Tolerance",
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Donor CD34+ and CD3+ cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jeffrey Veale, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-11-06",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707262"
    },
    {
      "nct_id": "NCT00450827",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-08",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450827"
    },
    {
      "nct_id": "NCT00890656",
      "title": "Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide (CTX)",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Decadron",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Ara-C",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 90,
      "start_date": "2003-06",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2012-02-20",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890656"
    },
    {
      "nct_id": "NCT02851056",
      "title": "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Survivin Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Prevnar 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Granulocyte-colony Stimulating Factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2016-09-27",
      "completion_date": "2018-08-09",
      "has_results": false,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02851056"
    },
    {
      "nct_id": "NCT00003294",
      "title": "Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 24,
      "start_date": "1997-05",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2011-03-07",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003294"
    },
    {
      "nct_id": "NCT00189137",
      "title": "Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma, Soft Tissue"
      ],
      "interventions": [
        {
          "name": "ifosfamide and doxorubicin vs gemcitabine and docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2004-08",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00189137"
    },
    {
      "nct_id": "NCT02383212",
      "title": "Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 398,
      "start_date": "2015-02-02",
      "completion_date": "2019-11-18",
      "has_results": false,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 40,
      "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02383212"
    },
    {
      "nct_id": "NCT02343666",
      "title": "HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus 1 Positive",
        "Stage I Adult Hodgkin Lymphoma",
        "Stage I Adult Non-Hodgkin Lymphoma",
        "Stage II Adult Hodgkin Lymphoma",
        "Stage II Adult Non-Hodgkin Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Non-Hodgkin Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "O6-Benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-08-15",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343666"
    },
    {
      "nct_id": "NCT00050531",
      "title": "High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myeloid, Chronic"
      ],
      "interventions": [
        {
          "name": "Gleevec",
          "type": "DRUG"
        },
        {
          "name": "Peg-alpha interferon (Peg-Intron)",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim (GM-CSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2003-04",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-05-11",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050531"
    },
    {
      "nct_id": "NCT02105766",
      "title": "Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Stem Cell Transplantation",
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "4 Years to 80 Years"
      },
      "enrollment_count": 56,
      "start_date": "2014-04-21",
      "completion_date": "2027-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-15T12:16:06.977Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02105766"
    }
  ]
}